From the impact of stringent regulations to the shift toward new indications and rising market segments, SmartTRAK explores some of the trends to watch for in 2022 and beyond.

Orthopedic regenerative medicine therapy as an emerging area of science holds great promise for treating and promoting faster healing in a variety of injuries. There is also a belief among some scientists and industry stakeholders that it may hold the key to halting or reversing degenerative chronic conditions through self-healing. In a previous article, SmartTRAK had highlighted several challenges that Regenerative Medicine therapies would need to overcome to become a fully viable business and recognized treatment solution for patients. In 2021, businesses, societies and health care systems across the world continued to experience disruptions from the COVID-19 pandemic and its subsequent waves of variants. Furthermore, much greater scrutiny and tougher regulations for some of the injectable regenerative medicine therapies were put into place. The start of 2022 is also not quite as “rosy” as most had hoped for ...

Jointechlabs – Emerging leader in point-of-care regenerative and rejuvenation medicine therapies

Nathan Katz PhD, ALBB, Co-founder, CEO and Chief Technical Officer at Jointechlabs* (JTL) discussed the Company’s unique technology platform and product developments in a recent interview with SmartTRAK.

JTL is a privately-held regenerative medicine solutions company based in North Barrington, IL. As an emerging leader in point-of-care regenerative and rejuvenation medicine therapies, JTL has patented, portable medicine products that enable personalized therapies. The Company’s lead product, MiniTC*, is an FDA-cleared portable medical device for isolation of fragmented and purified fat grafts (microfat) at the point-of-care. Additionally, JTL is developing therapies for unmet medical needs, with its first product candidate, JTL-T-01*, a proprietary injectable stem cell scaffold in clinical development as a biologic therapy for osteoarthritis, for approval under the FDA’s fast-track program.

SmartTRAK: Can you first tell us a little bit about yourself and then about Jointechlabs?

Nathan Katz: I have a medical background. I graduated from medical school back many years ago in Russia, then graduated from Tel Aviv University and acquired my Master’s Degree and PhD in Cell Biology. I came to the US 16 years ago, first, working on genetics and embryonic stem cells. I spent quite a lot of time in research with embryonic stem cells in the first decade of this millennia and then I was looking for the technology that could be translated into applicable medical technology and translated into therapy.

Adult stem cells came up as the first and obvious choice to look at more precisely, so we shifted, and I shifted personally, my focus from embryonic stem cells towards adult stem cells. I came across PadZuke, and Patricia, who published the first publication on actual adipose-derived stem cells in 2001. My idea was that it is the right way to go and could lead to ...

To read the entire interview with Dr. Katz, please click the button below to download the complete transcript.

---

SmartTRAK is the leading source of competitive intelligence used by the top ten global wound care & orthopedics companies. If you would like a demo of what SmartTRAK has to offer and how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.

We are pleased to announce that Jim Petricek has joined the team at SmartTRAK as General Manager, Orthobiologics and Regenerative Medicine. Jim has 20+ years operational and management consulting experience in orthobiologics and regenerative medicine with roles in product development, marketing and business development, including prior management positions with BioMimetic Therapeutics and Synthes.

Meet Jim Petricek:

What is your role with SmartTRAK? General Manager Orthobiologics and Regenerative Medicine; Lead Analyst Orthobiologics

What do you like about SmartTRAK? I’ve had the pleasure of interacting with SmartTRAK for many years. The group is very knowledgeable in their respective fields, and while I’m sure not every day is bliss, there is a very palpable sense that everyone really enjoys being part of the SmartTRAK team.

Dr. Wasik Ashraf, an Orthopaedic Surgeon specializing in Sports Medicine, discusses trends and innovation in Orthobiologics and Regenerative Medicine in an interview with SmartTRAK.

In this wide-ranging interview, Dr. Ashraf gives his view of CMS' FY21 OPPS-ASC Final Rulemaking, and discusses emerging trends and innovation in OrthoBiologics and Regenerative Medicine. As a Board-certified and fellowship-trained physician specializing in sports medicine, joint preservation and cartilage restoration, Dr. Ashraf offers his unique view and perspective on some of the newest technologies he is using, as well as those to look out for in the coming years. 

To listen to the interview, recorded live via Uberconference, click on the following video (41:37 min). A transcript of the interview is also available below.

As states begin to loosen restrictions and we try and put COVID-19 in the rear view mirror, in the words of Bill Gates, "it's going to be a while before we can get back to normal" and companies are going to have to find creative ways to stay connected and engaged while moving forward and getting work done.

The following is a small sampling of Regenerative Medicine segment updates from the past week that were compiled, reviewed and posted in real-time by our SmartTRAK analysts, who are constantly monitoring the situation and sifting through the noise to present news, analysis, studies, trial results, patents and financial data that are most relevant to our subscribers.

The GID Group – Prepping to revolutionize Regenerative Medicine with an innovative modular tissue processing platform

In December, at IFATS 2019, William “Bill” Cimino, PhD, CEO of The GID Group (GID) sat down with SmartTRAK to discuss the Company’s novel modular tissue processing platform, which reduces an entire GMP cell-processing facility to a single disposable device, enabling physicians to extract and process adipose tissue in real time for use in a wide range of applications.

GID is a privately held, clinical stage cellular medicine company currently working on developing a tissue processing platform, the GID SVF-2 device, that enables cell-based treatments.

To find out more about the GID Group, its revolutionary technology and product candidate, click on the following video to listen to SmarTRAK’s interview with Bill Cimino, recorded live at the IFATS Annual Meeting held in Marseille, France December 3-7, 2019. A transcript of the interview is also provided below.

Location: Northeast region of US (NY, NJ, MA, PA)

Full-time Position

Position:

BioMedGPS, a leading strategic advisory and healthcare analytics firm serving the life sciences industry, is seeking a Director of Enterprise Sales with extensive healthcare B2B experience for its SmartTRAK Business Intelligence platform and related products. Applicant must reside in the Northeastern region of the USA for easy access to major accounts.

SmartTRAK is the first business intelligence portal that provides real time data, analytics and curated content by a team of industry experts to help medical device executives make more informed strategic decisions. SmartTRAK is utilized by leading medical device companies within the orthopedic, wound care, regenerative medicine and neuro therapeutic areas. The Director of Sales will be responsible for selling SmartTRAK’s suite of business intelligence solutions to C- suite and other senior level executives, as well as building long term strategic programs and relationships at all levels of the enterprise.

The US Surgical Matrices Market continued its modest growth in Q219, with growth in breast matrices continuing to outpace hernia matrices.

SmartTRAK reports that the US Surgical Matrices market, comprised of matrices used for Breast Reconstruction and Hernia Repair, experienced single digit growth in Q219 according to SmartTRAK estimates. The fast-growing Breast Reconstruction segment slowed to +4.6% YoY during the quarter, while the US Hernia Repair market ticked up slightly to +2.9% YoY.

Among the many topics covered in the Q219 US Surgical Matrices Market Recap* are:

OrthogenRx CEO & Founder Michael Daley talks about the Company’s new 3-injection HA product, TriVisc and what will come next.

Michael Daley, CEO & Founder of OrthogenRx, a US medical device company focused on treatments for musculoskeletal conditions, talked about TriVisc, the Company’s new 3-injection hyaluronic acid (HA) product for knee osteoarthritis, as well as the future at OrthogenRx, in an interview with SmartTRAK at the American Academy of Orthopaedic Surgeons 2019 Annual Meeting held March 12-14, 2019 in Las Vegas, NV.

What is the rational for OrthogenRx to bring TriVisc now to a very crowded 3-injection HA segment?

To have a presence in the entire US HA market, OrthogenRx aims to provide...